Janux Therapeutics, a pioneering clinical-stage biopharmaceutical company, has successfully raised an impressive $350 million in a recent funding round aimed at advancing its groundbreaking immunotherapy platform. This substantial investment underscores the increasing confidence investors have in Janux’s innovative approach to cancer treatment. With its advanced platform masking technology, Janux is engineering novel drug candidates specifically designed to elicit tumor-specific immune responses, allowing the immune system to effectively target and destroy cancer cells while preserving healthy tissue. This represents a significant breakthrough in addressing the toxicity and efficacy limitations often associated with traditional T cell engagers. The funds raised will be strategically utilized to accelerate clinical trials and further the development of its promising drug candidates, moving closer to providing patients with effective cancer therapies that minimize side effects. Additionally, Janux is proud to emphasize its commitment to fostering a vibrant workplace culture, having earned a Great Place To Work Certification™ in 2024, which reflects its dedication to employee satisfaction and inclusivity. This funding marks a pivotal moment for Janux Therapeutics as it seeks to reshape the landscape of cancer immunotherapy and bring hope to patients battling this devastating disease. With the support of this investment, Janux is poised to make significant strides in its mission to revolutionize cancer treatment through its innovative and patient-focused immunotherapy solutions.
Janux Therapeutics Secures $350 Million in Funding for Innovative Immunotherapy Development
Recently funded · $350.0MBiotechnology
Get the full Janux Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
